The MaxCyte STX can transfect from 5E5 to 1E10 cells with comparable results from small bench scale through screening and cGMP manufacturing.
MaxCyte STX demonstrated the potential to achieve gram-scale antibody and protein production in an appropriate biomanufacturing host cell line with a simple 20-30 minute transfection run, the company said.
MaxCyte CEO and President Douglas Doerfler said the company is happy to announce the gram-scale antibody and protein yields achieved by users of the MaxCyte STX in standard biomanufacturing cell lines like CHO.
"Companies are no longer limited to settling for surrogate or non-relevant systems like HEK in order to generate enough protein or antibody for the development and screening of therapeutic biopharmaceuticals," Doerfler added.